Islatravir/lenacapavir vs Lenacapavir (Sunlenca)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV capsid · full HIV pipeline

Islatravir/lenacapavir

Developed by Gilead Sciences and partners

Phase 3 in HIVsmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Lenacapavir (Sunlenca)

Marketed by Gilead Sciences

Approved in HIVsmall molecule
Partial signal

NCT04143594 · Phase 2 · completed

The trial randomized 183 participants to lenacapavir-containing regimens or the active comparator B/F/TAF, but treatment was not blinded. The primary HIV-1 RNA suppression endpoint was a clinically relevant measure, yet all lenacapavir-versus-comparator comparisons were non-significant, so the results provide real but limited evidence for lenacapavir.

Next expected readout: March 2027 · NCT06749054 (registry estimate)

Reported efficacy

Percentage of Participants in Cohort 1 Achieving a Reduction of ≥ 0.5 log10 Copies/mL in Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) From Baseline to the End of Functional Monotherapy Period (Baseline up to Day 1 SC Visit (14 days after the first dose of oral lencapavir) or Day 15): Percentage of Participants in Cohort 1 Achieving a Reduction of ≥ 0.5 log10 Copies/mL in Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) From Baseline to the End of Functional Monotherapy Period (Baseline up to Day 1 SC Visit (14 days after the first dose of oral lencapavir) or Day 15): Cohort 1A: Lenacapavir 87.5 percentage of participants | Cohort 1B: Placebo to Lenacapavir 16.7 percentage of participants (met)

Result source: NCT04150068

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIslatravir/​lenacapavirLenacapavir (Sunlenca)
HIV-1 RNA below 50 copies/mL (week 48)—Trial running · NCT0663028690.4% vs 92%vs B/F/TAFwk 54 · n 52NCT04143594
11 other results
  • 84.9% vs 92% wk 54 · n 53 · Phase 2 · primary NCT04143594
  • 84.6% vs 92% wk 54 · n 52 · Phase 2 · primary NCT04143594
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594
  • 75.5% vs 92% wk 80 · n 53 · Phase 2 · secondary NCT04143594
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594
  • 90.4% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 88.7% vs 96% wk 38 · n 53 · Phase 2 · secondary NCT04143594
  • 88.5% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594
  • 92.5% vs 100% wk 28 · n 53 · Phase 2 · secondary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594
HIV-1 RNA 50 copies/mL or more (week 48)—Trial running · NCT06630286—Trial running · NCT06532656
CD4 count, change (week 48)—Trial running · NCT06630286275 vs 248vs B/F/TAFwk 80 · n 48NCT04143594
11 other results
  • 262 vs 248 wk 80 · n 41 · Phase 2 · secondary NCT04143594
  • 245 vs 248 wk 80 · n 46 · Phase 2 · secondary NCT04143594
  • 204 vs 193 wk 54 · n 49 · Phase 2 · secondary NCT04143594
  • 213 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 220 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 195 vs 232 wk 38 · n 49 · Phase 2 · secondary NCT04143594
  • 220 vs 232 wk 38 · n 51 · Phase 2 · secondary NCT04143594
  • 211 vs 232 wk 38 · n 46 · Phase 2 · secondary NCT04143594
  • 172 vs 163 wk 28 · n 49 · Phase 2 · secondary NCT04143594
  • 158 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594
  • 206 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594

HIV-1 RNA below 50 copies/mL (week 48)

Islatravir/​lenacapavir
—Trial running · NCT06630286
Lenacapavir (Sunlenca)
90.4% vs 92%vs B/F/TAFwk 54 · n 52NCT04143594
11 other results
  • 84.9% vs 92% wk 54 · n 53 · Phase 2 · primary NCT04143594
  • 84.6% vs 92% wk 54 · n 52 · Phase 2 · primary NCT04143594
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594
  • 75.5% vs 92% wk 80 · n 53 · Phase 2 · secondary NCT04143594
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594
  • 90.4% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 88.7% vs 96% wk 38 · n 53 · Phase 2 · secondary NCT04143594
  • 88.5% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594
  • 92.5% vs 100% wk 28 · n 53 · Phase 2 · secondary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594

HIV-1 RNA 50 copies/mL or more (week 48)

Islatravir/​lenacapavir
—Trial running · NCT06630286
Lenacapavir (Sunlenca)
—Trial running · NCT06532656

CD4 count, change (week 48)

Islatravir/​lenacapavir
—Trial running · NCT06630286
Lenacapavir (Sunlenca)
275 vs 248vs B/F/TAFwk 80 · n 48NCT04143594
11 other results
  • 262 vs 248 wk 80 · n 41 · Phase 2 · secondary NCT04143594
  • 245 vs 248 wk 80 · n 46 · Phase 2 · secondary NCT04143594
  • 204 vs 193 wk 54 · n 49 · Phase 2 · secondary NCT04143594
  • 213 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 220 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 195 vs 232 wk 38 · n 49 · Phase 2 · secondary NCT04143594
  • 220 vs 232 wk 38 · n 51 · Phase 2 · secondary NCT04143594
  • 211 vs 232 wk 38 · n 46 · Phase 2 · secondary NCT04143594
  • 172 vs 163 wk 28 · n 49 · Phase 2 · secondary NCT04143594
  • 158 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594
  • 206 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Islatravir/lenacapavir: no structured comparison results are available for HIV.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Islatravir/lenacapavir: 0 of 4 rows · Lenacapavir (Sunlenca): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLenacapavir (Sunlenca)
Dropout rate
21.2%Group 1: SC LEN+(F/TAF→ TAF)a
NCT04143594 · Phase 2 · combination
show 7 more results
34%Group 2: SC LEN + (F/TAF → BIC)
NCT04143594 · Phase 2 · combination
30.8%Group 3: Oral LEN + F/TAF
NCT04143594 · Phase 2 · combination
16.7%750 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
16.7%450 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
14.3%150 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
0%50 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
0%20 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
1.9%Group 1: SC LEN+(F/TAF→ TAF)a
NCT04143594 · Phase 2 · combination
show 7 more results
0%Group 2: SC LEN + (F/TAF → BIC)
NCT04143594 · Phase 2 · combination
0%Group 3: Oral LEN + F/TAF
NCT04143594 · Phase 2 · combination
—750 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
—450 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
—150 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
—50 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
—20 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
Serious AEs
7.7%Group 1: SC LEN+(F/TAF→ TAF)a
NCT04143594 · Phase 2 · combination
show 7 more results
7.5%Group 2: SC LEN + (F/TAF → BIC)
NCT04143594 · Phase 2 · combination
13.5%Group 3: Oral LEN + F/TAF
NCT04143594 · Phase 2 · combination
0%750 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
16.7%450 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
0%150 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
0%50 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
0%20 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
injection site erythema 48.1%
injection site swelling 32.7%
injection site pain 28.8%
NCT04143594 · Phase 2 · combination
show 7 more results
injection site erythema 34%
injection site swelling 34%
injection site pain 26.4%
NCT04143594 · Phase 2 · combination
covid-19 21.2%
influenza 21.2%
headache 17.3%
NCT04143594 · Phase 2 · combination
750 mg
injection site pain 80% (placebo 30%)
injection site erythema 40% (placebo 10%)
injection site nodule 40% (placebo 0%)
NCT03739866 · Phase 1 · registry result, not featured evidence
450 mg
injection site pain 66.7% (placebo 30%)
upper respiratory tract infection 66.7% (placebo 0%)
injection site erythema 33.3% (placebo 10%)
NCT03739866 · Phase 1 · registry result, not featured evidence
150 mg
injection site erythema 66.7% (placebo 10%)
injection site pain 66.7% (placebo 30%)
injection site induration 50% (placebo 10%)
NCT03739866 · Phase 1 · registry result, not featured evidence
50 mg
injection site pain 66.7% (placebo 30%)
syphilis 33.3% (placebo 0%)
acne 16.7% (placebo 0%)
NCT03739866 · Phase 1 · registry result, not featured evidence
20 mg
headache 33.3% (placebo 20%)
anogenital dysplasia 16.7% (placebo 0%)
conjunctivitis allergic 16.7% (placebo 0%)
NCT03739866 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lenacapavir (Sunlenca)

HIV-1 RNA Less Than 50 Copies 20% (n=5) vs 0% (n=10) placebo @ 1.4wk750 mg
responder rate · % of participants
NCT03739866 · Phase 1 · registry result, not featured evidence
show 16 more results
16.7% (n=6) vs 0% (n=10) placebo @ 1.4wk450 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
0% (n=6) vs 0% (n=10) placebo @ 1.4wk150 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
16.7% (n=6) vs 0% (n=10) placebo @ 1.4wk50 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
0% (n=6) vs 0% (n=10) placebo @ 1.4wk20 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
90.4% (n=52) vs 92% (n=25) B/F/TAF @ 54wk
NCT04143594 · Phase 2 · combination
84.9% (n=53) vs 92% (n=25) B/F/TAF @ 54wk
NCT04143594 · Phase 2 · combination
84.6% (n=52) vs 92% (n=25) B/F/TAF @ 54wk
NCT04143594 · Phase 2 · combination
94.2% (n=52) vs 100% (n=25) B/F/TAF @ 28wk
NCT04143594 · Phase 2 · combination
92.5% (n=53) vs 100% (n=25) B/F/TAF @ 28wk
NCT04143594 · Phase 2 · combination
94.2% (n=52) vs 100% (n=25) B/F/TAF @ 28wk
NCT04143594 · Phase 2 · combination
90.4% (n=52) vs 96% (n=25) B/F/TAF @ 38wk
NCT04143594 · Phase 2 · combination
88.7% (n=53) vs 96% (n=25) B/F/TAF @ 38wk
NCT04143594 · Phase 2 · combination
88.5% (n=52) vs 96% (n=25) B/F/TAF @ 38wk
NCT04143594 · Phase 2 · combination
86.5% (n=52) vs 92% (n=25) B/F/TAF @ 80wk
NCT04143594 · Phase 2 · combination
75.5% (n=53) vs 92% (n=25) B/F/TAF @ 80wk
NCT04143594 · Phase 2 · combination
86.5% (n=52) vs 92% (n=25) B/F/TAF @ 80wk
NCT04143594 · Phase 2 · combination
HIV-1 RNA -2.26 vs -0.17 placebo log750 mg
absolute change · log
NCT03739866 · Phase 1 · registry result, not featured evidence
show 16 more results
-2.2 vs -0.17 placebo log450 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
-1.76 vs -0.17 placebo log150 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
-1.79 vs -0.17 placebo log50 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
-1.35 vs -0.17 placebo log20 mg
NCT03739866 · Phase 1 · registry result, not featured evidence
-2.92 vs -3.07 B/F/TAF log @ 28wk
NCT04143594 · Phase 2 · combination
-3.04 vs -3.07 B/F/TAF log @ 28wk
NCT04143594 · Phase 2 · combination
-3.01 vs -3.07 B/F/TAF log @ 28wk
NCT04143594 · Phase 2 · combination
-2.96 vs -3.04 B/F/TAF log @ 38wk
NCT04143594 · Phase 2 · combination
-3.06 vs -3.04 B/F/TAF log @ 38wk
NCT04143594 · Phase 2 · combination
-3.02 vs -3.04 B/F/TAF log @ 38wk
NCT04143594 · Phase 2 · combination
-2.95 vs -3.08 B/F/TAF log @ 54wk
NCT04143594 · Phase 2 · combination
-3.12 vs -3.08 B/F/TAF log @ 54wk
NCT04143594 · Phase 2 · combination
-2.85 vs -3.08 B/F/TAF log @ 54wk
NCT04143594 · Phase 2 · combination
-2.96 vs -3.09 B/F/TAF log @ 80wk
NCT04143594 · Phase 2 · combination
-3.08 vs -3.09 B/F/TAF log @ 80wk
NCT04143594 · Phase 2 · combination
-2.96 vs -3.09 B/F/TAF log @ 80wk
NCT04143594 · Phase 2 · combination
CD4+ 172 vs 163 B/F/TAF cells/uL @ 28wk
absolute change · cells/uL
NCT04143594 · Phase 2 · combination
show 11 more results
158 vs 163 B/F/TAF cells/uL @ 28wk
NCT04143594 · Phase 2 · combination
206 vs 163 B/F/TAF cells/uL @ 28wk
NCT04143594 · Phase 2 · combination
195 vs 232 B/F/TAF cells/uL @ 38wk
NCT04143594 · Phase 2 · combination
220 vs 232 B/F/TAF cells/uL @ 38wk
NCT04143594 · Phase 2 · combination
211 vs 232 B/F/TAF cells/uL @ 38wk
NCT04143594 · Phase 2 · combination
204 vs 193 B/F/TAF cells/uL @ 54wk
NCT04143594 · Phase 2 · combination
213 vs 193 B/F/TAF cells/uL @ 54wk
NCT04143594 · Phase 2 · combination
220 vs 193 B/F/TAF cells/uL @ 54wk
NCT04143594 · Phase 2 · combination
275 vs 248 B/F/TAF cells/uL @ 80wk
NCT04143594 · Phase 2 · combination
262 vs 248 B/F/TAF cells/uL @ 80wk
NCT04143594 · Phase 2 · combination
245 vs 248 B/F/TAF cells/uL @ 80wk
NCT04143594 · Phase 2 · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Islatravir/lenacapavir's landscape · Lenacapavir (Sunlenca)'s landscape